Published in Eur Arch Psychiatry Clin Neurosci on March 04, 2017
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods (2007) 50.83
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
Molecular components of the mammalian circadian clock. Hum Mol Genet (2006) 7.51
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol (2001) 6.12
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
MAP kinases. Chem Rev (2001) 4.70
Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci (2007) 4.06
The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem (2001) 3.81
Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci (2002) 2.94
A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry (2010) 2.77
Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J Neurosci (2000) 2.64
Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol (2009) 2.60
The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci (2000) 2.52
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci (2005) 2.25
Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci (2007) 2.12
Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry (2010) 2.05
Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry (2009) 2.03
Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry (2006) 1.90
A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication. Nat Neurosci (2001) 1.81
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv (2009) 1.77
Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum Mol Genet (2010) 1.72
Genome-wide association scan of trait depression. Biol Psychiatry (2010) 1.65
Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology (2010) 1.56
No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand (2009) 1.49
Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol (1999) 1.48
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem (1999) 1.36
Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis (2008) 1.28
Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes Brain Behav (2006) 1.28
Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology (2005) 1.26
Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage (2010) 1.24
A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology (2010) 1.21
Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res (1997) 1.20
BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology (2012) 1.16
Counting on mitogen-activated protein kinases--ERKs 3, 4, 5, 6, 7 and 8. Cell Signal (2004) 1.09
Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. Neuropharmacology (2008) 1.08
Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem (2001) 1.06
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 1.06
Corticosterone regulates pERK1/2 map kinase in a chronic depression model. Ann N Y Acad Sci (2008) 1.04
Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2013) 1.03
Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up? J Affect Disord (2004) 1.02
Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics (2011) 0.99
BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology (2004) 0.98
Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol (2011) 0.96
Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons. J Neurochem (2007) 0.96
Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology (2007) 0.96
Reduced reactivity to novelty, impaired social behavior, and enhanced basal synaptic excitatory activity in perforant path projections to the dentate gyrus in young adult mice deficient in the neural cell adhesion molecule CHL1. Mol Cell Neurosci (2006) 0.95
Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain Dev (2000) 0.94
Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J (2008) 0.93
Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci (2010) 0.91
Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. J Affect Disord (2013) 0.89
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet (2013) 0.89
Constitutive activity of serotonin 2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants. Mol Pharmacol (2010) 0.88
ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype. World J Biol Psychiatry (2011) 0.88
Identification of sialyltransferase 8B as a generalized susceptibility gene for psychotic and mood disorders on chromosome 15q25-26. PLoS One (2012) 0.87
Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson's disease. Mov Disord (2012) 0.86
Neuropeptide signaling differentially affects phase maintenance and rhythm generation in SCN and extra-SCN circadian oscillators. PLoS One (2011) 0.86
Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression. Pharmacogenet Genomics (2012) 0.86
European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol (2012) 0.86
Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics J (2006) 0.85
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep (2015) 0.84
Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.81
A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord (2011) 0.81
Stress downregulates hippocampal expression of the adhesion molecules NCAM and CHL1 in mice by mechanisms independent of DNA methylation of their promoters. Cell Adh Migr (2008) 0.79
PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J (2014) 0.79
BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet Genomics (2013) 0.78
Stress-induced activation of the brainstem Bcl-xL gene expression in rats treated with fluoxetine: correlations with serotonin metabolism and depressive-like behavior. Neuropharmacology (2011) 0.78
Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics J (2015) 0.78
Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine. Transl Psychiatry (2014) 0.78
Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design. J Psychosoc Nurs Ment Health Serv (2008) 0.78
Inhibition of glutamate release by bupropion in rat cerebral cortex nerve terminals. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.76
Effect of Bcl-2 rs956572 polymorphism on age-related gray matter volume changes. PLoS One (2013) 0.76
What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. World J Biol Psychiatry (2014) 0.76
Expression of Bcl2 family genes in the early phase of long-term potentiation. Bull Exp Biol Med (2014) 0.76
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. Eur Arch Psychiatry Clin Neurosci (2015) 0.85
Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. J Affect Disord (2015) 0.83
Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. J Neural Transm (Vienna) (2014) 0.78
Bipolar II disorder as a risk factor for postpartum depression. J Affect Disord (2016) 0.76
A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. Eur Neuropsychopharmacol (2014) 0.75
Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. Prog Neuropsychopharmacol Biol Psychiatry (2017) 0.75
Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci (2016) 0.75
High occupational level is associated with poor response to treatment of depression. Eur Neuropsychopharmacol (2016) 0.75
Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. Int Clin Psychopharmacol (2022) 0.75
Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. J Affect Disord (2015) 0.75